Emodepside + Praziquantel

Verify with FDA CVM →

4,931 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
4,931
Total Reports
214
Deaths Reported
430.0%
Death Rate

Active Ingredients

EmodepsidePraziquantel

Administration Routes

TopicalUnknownOralOtherOphthalmicTransdermalIntraocularSubcutaneous

Species Affected

Cat 4,589
Unknown 232
Human 72
Dog 36
Rabbit 1
Whale 1

Most Affected Breeds

Domestic Shorthair 3,145
Cat (unknown) 496
Domestic Longhair 322
Unknown 313
Domestic Mediumhair 301
Siamese 92
Maine Coon 46
Bengal 29
Russian 20
Ragdoll 18

Most Reported Reactions

Application site alopecia 1,127
Hypersalivation 827
Lethargy (see also Central nervous system depression in 'Neurological') 656
Vomiting 463
Ataxia 386
Lack of efficacy (endoparasite) - tapeworm 384
Behavioural disorder NOS 334
Anorexia 300
Application site erythema 267
Application site pruritus 265
Licking at application site 217
Accidental exposure 195

Outcome Breakdown

Outcome Unknown
2,622 (55.8%)
Recovered/Normal
1,574 (33.5%)
Ongoing
286 (6.1%)
Died
131 (2.8%)
Euthanized
83 (1.8%)
Recovered with Sequela
7 (0.1%)

Data Summary

Metric Value
Total adverse event reports 4,931
Reports involving death 214
Case-fatality rate (reported events) 430.0%
Distinct species in reports 6
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Emodepside + Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 4,931 adverse event reports referencing Emodepside + Praziquantel, including 214 reports in which the animal died — a 430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Emodepside, Praziquantel. Reported administration routes include Topical, Unknown, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Emodepside + Praziquantel reports are Cat (4,589 reports), Unknown (232 reports), Human (72 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (3,145), Cat (unknown) (496), Domestic Longhair (322) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Emodepside + Praziquantel are Application site alopecia (1,127), Hypersalivation (827), Lethargy (see also Central nervous system depression in 'Neurological') (656), Vomiting (463). Of the 4,703 reports with a coded outcome, Outcome Unknown is the leading category at 55.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Emodepside + Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial